Biotech company Novavax announced that the first doses of its Nuvaxovid COVID-19 vaccine (recombinant, adjuvanted) have begun shipping to EU member states. Nuvaxovid, also known as NVX-CoV2373, is the first protein-based COVID-19 vaccine authorized for use in Europe. In August 2021, Novavax and the European Commission (EC) signed an advance purchase agreement for up to 100 million doses of Nuvaxovid, with the option for an additional 100 million doses. The doses will be shipping from Novavax' Netherlands distribution center starting this week. The first wave of shipments features several countries, such as Austria, France and Germany. "... The Novavax COVID-19 vaccine provides a differentiated option to bolster vaccination rates across Europe," says Stanley C. Erck, Novavax's president and CEO.